MX341110B - Inhibidores de la amida hidrolasa de acidos grasos (faah). - Google Patents
Inhibidores de la amida hidrolasa de acidos grasos (faah).Info
- Publication number
- MX341110B MX341110B MX2013006598A MX2013006598A MX341110B MX 341110 B MX341110 B MX 341110B MX 2013006598 A MX2013006598 A MX 2013006598A MX 2013006598 A MX2013006598 A MX 2013006598A MX 341110 B MX341110 B MX 341110B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- disclosure
- faah inhibitors
- faah
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
Abstract
La presente descripción se relaciona con compuestos útiles como inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH). La descripción proporciona, además, composiciones farmacéuticamente aceptables que comprenden los compuestos de la descripción y métodos para usar las composiciones en el tratamiento de diversos trastornos. Los compuestos de la invención se describen en la Tabla 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426362P | 2010-12-22 | 2010-12-22 | |
US201161446808P | 2011-02-25 | 2011-02-25 | |
PCT/US2011/066972 WO2012088469A1 (en) | 2010-12-22 | 2011-12-22 | Faah inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013006598A MX2013006598A (es) | 2013-12-06 |
MX341110B true MX341110B (es) | 2016-08-09 |
Family
ID=45509695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006598A MX341110B (es) | 2010-12-22 | 2011-12-22 | Inhibidores de la amida hidrolasa de acidos grasos (faah). |
Country Status (18)
Country | Link |
---|---|
US (1) | US9657012B2 (es) |
EP (1) | EP2655356B1 (es) |
JP (1) | JP5982397B2 (es) |
KR (1) | KR20140002709A (es) |
CN (1) | CN103502237B (es) |
AR (1) | AR084433A1 (es) |
AU (1) | AU2011348113A1 (es) |
BR (1) | BR112013016154A2 (es) |
CA (1) | CA2822842C (es) |
CL (1) | CL2013001772A1 (es) |
CO (1) | CO6781493A2 (es) |
ES (1) | ES2601499T3 (es) |
MX (1) | MX341110B (es) |
NZ (1) | NZ611798A (es) |
RU (1) | RU2013133884A (es) |
TW (1) | TW201307284A (es) |
UY (1) | UY33832A (es) |
WO (1) | WO2012088469A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010085589A2 (en) | 2009-01-22 | 2010-07-29 | G&H Brands Llc | Desensitizing drug product |
CA2871778C (en) | 2012-05-03 | 2022-09-13 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
WO2014004676A1 (en) * | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
ES2723969T3 (es) | 2014-06-19 | 2019-09-04 | Merial Inc | Composiciones parasiticidas que comprenden derivados de indol, procedimientos y usos de las mismas |
WO2016144860A1 (en) | 2015-03-06 | 2016-09-15 | Ironwood Pharmaceuticals, Inc. | Faah inhibitors for the treatment or prevention of nausea |
WO2016154028A1 (en) | 2015-03-26 | 2016-09-29 | Iversen Jacqueline M | Methods and compositions to inhibit symptoms associated with veisalgia |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
US20210355084A1 (en) * | 2018-06-26 | 2021-11-18 | Northeastern University | N-substituted indoles and use as allosteric modulators of cannabinoid receptors |
CN108912112A (zh) * | 2018-08-14 | 2018-11-30 | 李敬敬 | 一种化合物、制备方法以及其在治疗疼痛中的应用 |
US11390601B2 (en) * | 2020-07-31 | 2022-07-19 | University Of Sharjah | Conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment |
CN111743864B (zh) * | 2020-08-05 | 2022-04-01 | 牡丹江医学院 | 一种体育外伤喷雾剂及其制备方法 |
WO2022204140A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of California | Algostatic agents for preventing transition from acute to chronic pain |
CN115616216A (zh) * | 2021-07-15 | 2023-01-17 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7337M (es) | 1968-01-11 | 1969-10-13 | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB1436771A (en) | 1973-02-16 | 1976-05-26 | Labaz | Indole derivatives and process for preparing the same |
SE421917B (sv) | 1976-01-21 | 1982-02-08 | Roussel Uclaf | Analogiforfarande for framstellning av nya derivat av 2-metyl-1-indolyl-ettikssyra med terapeutisk verkan |
US4460777A (en) | 1981-11-19 | 1984-07-17 | Ciba-Geigy Corporation | N-Substituted-2-pyridylindoles |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US5965582A (en) | 1994-08-03 | 1999-10-12 | Asta Medica Aktiengesellschaft | N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect |
JPH11503445A (ja) | 1995-04-10 | 1999-03-26 | 藤沢薬品工業株式会社 | cGMP−PDE阻害剤としてのインドール誘導体 |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
DE19636150A1 (de) | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
IL137540A0 (en) | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
PL343007A1 (en) | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
DE19946301A1 (de) | 1998-04-02 | 2001-04-19 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften |
DE19814838C2 (de) | 1998-04-02 | 2001-01-18 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung |
ES2262072T3 (es) | 1998-04-28 | 2006-11-16 | Elbion Ag | Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4. |
US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
EP1156855A1 (en) | 1999-03-01 | 2001-11-28 | Ortho-McNeil Pharmaceutical, Inc. | Composition comprising a tramadol material and a selective cox-2 inhibitor drug |
WO2000067802A1 (en) | 1999-05-10 | 2000-11-16 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
AU2050001A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Synthesis of indole-containing spla2 inhibitors |
AU2252201A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Carbon monoxide-based synthesis of spla2 inhibitors |
WO2001044182A2 (en) | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | New synthesis of spla2 inhibitors |
DE19962300A1 (de) | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
IT1315267B1 (it) | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
WO2001081306A2 (en) | 2000-04-19 | 2001-11-01 | Eli Lilly And Company | Azide cyclization-based synthesis and intermediates for spla2 inhibitors |
WO2001087834A1 (fr) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
IT1318641B1 (it) | 2000-07-25 | 2003-08-27 | Novuspharma Spa | Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale. |
DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
JP4399253B2 (ja) | 2001-06-20 | 2010-01-13 | ワイス | プラスミノゲンアクチベーターインヒビター−1(pai−1)のインヒビターとしての、置換されたインドール酸誘導体 |
US7419658B2 (en) | 2001-07-09 | 2008-09-02 | Euroscreen S.A. | Isolated ligand of ChemerinR |
WO2003022280A2 (en) | 2001-09-13 | 2003-03-20 | Synta Pharmaceuticals Corp. | 3-glyoxlylamideindoles for treating cancer |
US20030162825A1 (en) | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
IL161667A0 (en) | 2001-11-09 | 2004-09-27 | Scios Inc | Method and composition to treat cystic fibrosis |
US6903104B2 (en) | 2001-12-06 | 2005-06-07 | National Health Research Institutes | Indol-3-YL-2-oxoacetamide compounds and methods of use thereof |
US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
JP2006510672A (ja) | 2002-12-10 | 2006-03-30 | ワイス | プラスミノーゲン活性化因子の阻害因子−1(pai−1)の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体 |
DE10318611A1 (de) | 2003-04-24 | 2004-11-11 | Elbion Ag | 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika |
DE10318609A1 (de) | 2003-04-24 | 2004-11-11 | Elbion Ag | 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika |
US7205299B2 (en) | 2003-06-05 | 2007-04-17 | Zentaris Gmbh | Indole derivatives having an apoptosis-inducing effect |
US7211588B2 (en) | 2003-07-25 | 2007-05-01 | Zentaris Gmbh | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation |
DE10334040A1 (de) | 2003-07-25 | 2005-03-10 | Zentaris Gmbh | Neue N-substituierte Indolyl-3-glyoxylsäureamide, deren Verwendung als Arzneimittel und Verfahren zu deren Herstellung |
US20060052390A1 (en) | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
US20060058296A1 (en) | 2003-12-24 | 2006-03-16 | Scios, Inc. | Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase |
US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
WO2006015263A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
ES2246721B1 (es) | 2004-08-10 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos. |
WO2006052712A1 (en) | 2004-11-08 | 2006-05-18 | Baxter International Inc. | Nanoparticulate compositions of tubulin inhibitor |
WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
EP1931632A4 (en) | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
MX2008011015A (es) | 2006-02-27 | 2008-11-14 | Wyeth Corp | Inhibidores de pai-1 para tratamiento de afecciones musculares. |
AU2007297573A1 (en) | 2006-06-12 | 2008-03-27 | Viamet Pharmaceuticals, Inc. | Metallo-hydrolase inhibitors using metal binding moieties in combination with targeting moieties |
US20100160391A1 (en) | 2006-07-10 | 2010-06-24 | Hammock Bruce D | Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases |
NZ596024A (en) * | 2006-08-07 | 2013-07-26 | Ironwood Pharmaceuticals Inc | Indole compounds |
EP1902733A1 (en) | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
JP2010511041A (ja) | 2006-11-28 | 2010-04-08 | ジオファーム オンコロジー, インコーポレイテッド | インジブリンを含むインドリル−3−グリオキシル酸誘導体の癌を処置するための単独またはさらなる薬剤との組み合わせでの使用 |
US20090047246A1 (en) | 2007-02-12 | 2009-02-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
CN101016294A (zh) | 2007-03-13 | 2007-08-15 | 中国人民武装警察部队医学院 | 具有多种生物活性的取代吲哚-3-基草酰胺衍生物 |
US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
DE102007045476A1 (de) | 2007-09-21 | 2009-04-02 | Westfälische Wilhelms-Universität Münster | Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 |
CA2702468A1 (en) | 2007-10-12 | 2009-04-23 | University Of Connecticut | Therapeutic applications of fatty acid amide hydrolase inhibitors |
EP2445877B1 (en) | 2008-12-03 | 2014-07-23 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
ES2551085T3 (es) | 2009-03-23 | 2015-11-16 | Glenmark Pharmaceuticals S.A. | Proceso para preparar derivados de pirimidina-diona condensados, útiles como moduladores de TRPA1 |
EP2488025A4 (en) | 2009-10-15 | 2013-04-03 | Childrens Medical Center | SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT |
US20130224151A1 (en) * | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
WO2012088431A1 (en) * | 2010-12-23 | 2012-06-28 | Ironwood Pharmaceuticals, Inc. | Faah inhibitors |
-
2011
- 2011-12-20 AR ARP110104811A patent/AR084433A1/es not_active Application Discontinuation
- 2011-12-22 CA CA2822842A patent/CA2822842C/en active Active
- 2011-12-22 ES ES11811264.8T patent/ES2601499T3/es active Active
- 2011-12-22 UY UY0001033832A patent/UY33832A/es not_active Application Discontinuation
- 2011-12-22 JP JP2013546437A patent/JP5982397B2/ja not_active Expired - Fee Related
- 2011-12-22 EP EP11811264.8A patent/EP2655356B1/en active Active
- 2011-12-22 US US13/996,807 patent/US9657012B2/en active Active
- 2011-12-22 KR KR1020137019320A patent/KR20140002709A/ko not_active Application Discontinuation
- 2011-12-22 NZ NZ611798A patent/NZ611798A/en not_active IP Right Cessation
- 2011-12-22 RU RU2013133884/04A patent/RU2013133884A/ru unknown
- 2011-12-22 TW TW100148110A patent/TW201307284A/zh unknown
- 2011-12-22 WO PCT/US2011/066972 patent/WO2012088469A1/en active Application Filing
- 2011-12-22 CN CN201180068166.1A patent/CN103502237B/zh not_active Expired - Fee Related
- 2011-12-22 MX MX2013006598A patent/MX341110B/es active IP Right Grant
- 2011-12-22 BR BR112013016154A patent/BR112013016154A2/pt not_active IP Right Cessation
- 2011-12-22 AU AU2011348113A patent/AU2011348113A1/en not_active Abandoned
-
2013
- 2013-06-18 CL CL2013001772A patent/CL2013001772A1/es unknown
- 2013-07-19 CO CO13171786A patent/CO6781493A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN103502237B (zh) | 2016-01-20 |
KR20140002709A (ko) | 2014-01-08 |
TW201307284A (zh) | 2013-02-16 |
UY33832A (es) | 2012-07-31 |
US20150175599A1 (en) | 2015-06-25 |
CO6781493A2 (es) | 2013-10-31 |
BR112013016154A2 (pt) | 2018-07-10 |
CN103502237A (zh) | 2014-01-08 |
JP2014500332A (ja) | 2014-01-09 |
CL2013001772A1 (es) | 2013-12-27 |
WO2012088469A1 (en) | 2012-06-28 |
NZ611798A (en) | 2015-07-31 |
EP2655356A1 (en) | 2013-10-30 |
EP2655356B1 (en) | 2016-08-03 |
AR084433A1 (es) | 2013-05-15 |
CA2822842A1 (en) | 2012-06-28 |
CA2822842C (en) | 2019-06-04 |
MX2013006598A (es) | 2013-12-06 |
US9657012B2 (en) | 2017-05-23 |
JP5982397B2 (ja) | 2016-08-31 |
ES2601499T3 (es) | 2017-02-15 |
RU2013133884A (ru) | 2015-01-27 |
AU2011348113A1 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341110B (es) | Inhibidores de la amida hidrolasa de acidos grasos (faah). | |
PH12015501191A1 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
MX342128B (es) | Compuestos farmaceuticos. | |
MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
PH12014500053A1 (en) | Proteasome inhibitors | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
WO2008100977A3 (en) | Carbamates therapeutic release agents as amidase inhibitors | |
MX355907B (es) | Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos. | |
MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
IN2014DN10386A (es) | ||
WO2011123719A3 (en) | Use of faah inhibitors for treating abdominal, visceral and pelvic pain | |
IN2013MN00501A (es) | ||
TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
WO2008024139A3 (en) | Inhibitors of fatty acid amide hydrolase | |
ZA201003352B (en) | Heterocyclic derivatives as modulators of ion channels | |
WO2007079180A3 (en) | Inhibitors of fatty acid amide hydrolase | |
MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
MX336742B (es) | Inhibidores de amida hidrolasa de acido graso. | |
WO2006104751A3 (en) | Methods and compositions for modulating rho-mediated gene transcription | |
WO2011151395A3 (en) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |